DIRS.INFO The most relevant business & tech news

☆ Eli Lilly's quarter was messy. What to do with the stock is more clear-cut
▼ + stars: | 2024-10-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

The report was messy, but it doesn't dim Eli Lilly's bright multiyear outlook, rendering the dip in the stock as a chance to buy. LLY .SPX 5Y mountain Eli Lilly's five-year stock performance compared with the S & P 500. Bottom line We're upgrading Eli Lilly to our buy-equivalent 1 rating and leaving our price target of $1,000 a share unchanged. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. Eli Lilly's new Alzheimer's drug Kisunla, which was approved by the FDA in July, was not a major focus on the call.

Persons: Eli Lilly, Eli, Eli Lilly's, Jim Cramer, Jim, —, that's, David Ricks, Ricks, Semaglutide, Wegovy, Lilly, There's, Mounjaro, Trulicity, Verzenio, Jim Cramer's, Cristina Arias Organizations: Revenue, The Club, CNBC, JPMorgan, Novo Nordisk, Food, Novo Nordisk's, FDA, Zepbound, Biogen, Merck, Pfizer, Morphic, Company, Pharmaceutical Locations: Tuesday's, U.S, Novo, Eisai, FactSet, Zepbound, Alcobendas, Madrid, Spain

☆ We see two post-earnings declines as buys, while happy to see a Tuesday laggard stabilize
▼ + stars: | 2024-10-30 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Then there were selloffs in Club stocks Eli Lilly and Advanced Micro Devices after their earnings releases. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Lilly's, AMD's financials, Stanley Black, Decker, Estee Lauder, Jim Cramer's, Jim Organizations: CNBC, Dow, Caterpillar, Devices, Nasdaq, Microsoft, Starbucks, MGM Resorts, Linde, Merck, ConocoPhillips, Mastercard, Roblox, Myers, Jim Cramer's Charitable Locations: Bristol

☆ Are you in perimenopause? Here’s what to look for, according to a doctor
▼ + stars: | 2024-10-30 | by ( Katia Hetter | ) edition.cnn.com time to read: +9 min

Many women start experiencing menopausal symptoms during those years of perimenopause, such as irregular periods, fatigue, sleep disturbances, hot flashes and weight gain. For most women, periods don’t stop suddenly, although there are exceptions when menopause is induced by surgery or certain medical treatments that stop ovarian function. Perimenopause is the several years preceding menopause, so the most common age for women to begin perimenopause is in their 40s. During perimenopause, hormone levels fluctuate a lot, and a test one day may look very different than one the next. CNN: Where should people go for more information on perimenopause and menopause?

Persons: Leana Wen, Wen, Perimenopause, Marcos Calvo, that’s, perimenopause Organizations: CNN, George Washington University, US Department of Health, Human Services, Women’s Health, Getty Locations: perimenopause

☆ Eli Lilly shares could be set for a big move if the Zepbound maker adds to its winning streak
▼ + stars: | 2024-10-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.

Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, —, Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S

☆ Weight loss care is leading IPO-hopeful Omada Health's latest growth surge as Ozempic boom continues
▼ + stars: | 2024-10-29 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +6 min

The startup says care for GLP-1 patients has become its most popular front door for new customers. AdvertisementLast spring, diabetes startup Omada Health said it wanted to help employers manage patients taking a blockbuster new class of weight-loss drugs. Omada Health's metabolic health program has now become the entry point for most new employers considering contracts with Omada Health, Duffy said. Launched in 2011, Omada provides virtual care for diabetes, hypertension, musculoskeletal care, and diabetes prevention, alongside obesity, to employers, health plans, and even health systems. The firm said GLP-1 drugs for obesity account for about 10% of all pharmacy spending.

Persons: —, Duffy, Omada, haven't, buzzy, Willis Towers Watson Organizations: Service, Omada Health, Business, Nordisk's Ozempic Locations: WeightWatchers, GLP

☆ What are endocrine-disrupting chemicals? Experts explain
▼ + stars: | 2024-10-29 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +9 min

The question is how worried should people be about these endocrine-disrupting chemicals (EDCs), such as phthalates, BPA or bisphenol A, and brominated flame retardants? Endocrine-disrupting chemicals are not produced by the human body but influence the way your hormones function, Bloom said. CNN reached out to the National Pest Management Association and the Personal Care Products Council for comment. Gradually replacing personal care products one at a time as you use up individual products is a great place to start, she said. “But personal care products is one thing where I think folks have a lot of autonomy and what they’re purchasing within reason.”

Persons: United States –, Michael Bloom, Bloom, ” Bloom, Alexa Friedman, ”, ” Friedman, Natalie Shaw, “, Friedman, – Friedman Organizations: CNN, George Mason University College of Public Health, Environmental, Cleveland Clinic, Endocrine Society, “, Pediatric Neuroendocrinology Group, National Institute of Environmental Health Sciences, Pesticides, National Pest Management Association, Care Products Council, US Environmental Protection Agency, EPA, allergists, Mayo Clinic Locations: United States, EDCs, Fairfax , Virginia

☆ Just the Facts – Health and Healthcare: Steve Ballmer Talks Through the Numbers
▼ + stars: | 2024-10-28 | by ( Sponsor Post | ) www.businessinsider.com time to read: +11 min

Find out the impact of the US healthcare system and the health of Americans to our costs and lifespans. In this episode of "Just the Facts," Health and Healthcare. In 2022, 3.28 million Americans died, about 1% of our total population; nearly 3.67 million people were born. As of 2023, 6.7 million Americans over age 65 had been diagnosed with it. Of the $4 1/2 trillion dollars in health spending, 3.7 trillion was spent on personal healthcare, while 760 billion was spent on things like public health, health research, healthcare facilities, medical equipment, and the cost of running health insurance programs.

Persons: Steve Ballmer, USAFacts, COVID Organizations: Insider, LA Clippers, Healthcare, FBI, Medicare, Affordable, Health Locations: America, COVID, Alzheimer's, United States

☆ Lizzo’s Halloween costume draws inspiration from ‘South Park’ episode that referenced her and the weight-loss drug Ozempic
▼ + stars: | 2024-10-26 | by ( Dan Heching | ) edition.cnn.com time to read: +2 min

CNN —Lizzo has taken a rather silly reference to her on a recent “South Park” episode and elevated it to a hilarious Halloween costume. In her first picture, Lizzo posed in an old-school-style print ad that asked, “Need self love? Lose guilt, gain self confidence.” Her caption for the post read, “Ok Halloween… you can start now.”Subsequent posts included a video snippet showing Lizzo dancing in her costume in front of a cutout of “South Park” character Cartman, as audio from the show’s Ozempic episode played. “Lizzo helps you eat everything you want and keep physical activity to a minimum… Ask about the power of not giving a f**k, with Lizzo,” the commercial adds, along with a series of side effects. Lizzo has long advocated for body positivity and spoken out about the body shaming she faces on social media.

Persons: CNN — Lizzo, Lizzo, Cartman, ”, Sharon, Sheila, “, “ Lizzo, ” “, Trey Parker, Matt Stone, CNN’s Lisa Respers Organizations: CNN, FDA, University of Colorado Boulder Locations: Colorado, Lizzo, CNN’s Lisa Respers France

☆ Young men are getting testosterone boosts to feel stronger, sharper, and anxiety-free
▼ + stars: | 2024-10-26 | by ( Andréa Becker | ) www.businessinsider.com time to read: +19 min

He had low testosterone levels, in the range of 219 to 239 nanograms per deciliter. Take Alexis Ohanian, the 41-year-old Reddit cofounder and Serena Williams' husband, who recently posted on X about his (relatively high) testosterone levels. RoWhen LaSara's cofounder John Snedegar opened up his brick-and-mortar men's health clinic in 2017, "nobody" was specializing in men's sexual health, he said. But he typically recommends lifestyle changes, like more exercise, eating better, and getting good sleep, which all naturally help to boost testosterone levels. Researchers such as Berumen worry the branding of men's health clinics prop up impossible standards of manhood.

Persons: Kade, unmotivated, LaSara, Alexis Ohanian, Bryan Bedder, Serena Williams, Joe Rogan, Dax Shepard, it's, Peter Conrad said, endocrinologists, Charles, Édouard Brown, —, Dr, Justin Houman, John Snedegar, Evan Miller, what's, Justin Dubin, Derek, Dana, he's, Houman, Dubin, Snedegar, Gwen Berumen, Berumen Organizations: LaSara, TRT, Ro, CDC, T Center, Men's Health, ESPN, Telltale, Clinic, University of Texas, American Psychological Association, Miami Locations: Idaho, Florida, Cedars, Sinai, Los Angeles, New York City, LaSara, Texas, Miami , Florida, Southern California, California, Miami, bricklayers, Austin

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia. Another study, published in August, found that semaglutide appeared to cut the risk of dementia in people with Type 2 diabetes. Type 2 diabetes is a risk factor for dementia and Alzheimer’s. The study found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The biggest difference was seen when comparing patients who took semaglutide to those who took insulin: Semaglutide patients had a 70% lower risk of Alzheimer’s, the study found.

Persons: —, semaglutide, ”, Stephen Salloway, ” Salloway, Rong Xu, liraglutide, Xu, ” Xu, they’re, Salloway, they’ve, Donna Wilcock, there’s, ” Wilcock, Dr, Alberto Espay, Espay, What’s, “, ” Espay Organizations: Alzheimer’s Association, Conference, Novo Nordisk, Warren Alpert Medical, Brown University, Center, Artificial Intelligence, Case Western Reserve University School of Medicine, Drug Administration, ”, Alzheimer’s, Indiana University School of Medicine, University of Cincinnati College of Medicine Locations: Novo, Rhode Island, Ohio

☆ Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
▼ + stars: | 2024-10-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Novo Nordisk 's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Alzheimer's disease is often diagnosed in the mild dementia stage, when a person has significant trouble with memory and thinking. But the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. by 2050. Novo Nordisk, which did not fund the new Case Western study, is also examining semaglutide in a late-stage study on Alzheimer's patients. In the liraglutide research, data from a midstage trial found that the drug may slow the progression of Alzheimer's disease by protecting patients' brains.

Persons: Semaglutide, Dr, Rong Xu, it's, Xu, Eli Lilly, Wegovy, Eli Lilly's Organizations: Novo Nordisk, Alzheimer's Association, Case Western Reserve University, CNBC, Nordisk, Case, National Institutes of Health, GLP Locations: U.S, Novo

☆ Younger Asian American women had the second-lowest breast cancer rate. Why they’re now tied for No. 1.
▼ + stars: | 2024-10-20 | by ( Claire Wang | ) www.nbcnews.com time to read: +7 min

Four months later, she was diagnosed with triple-negative breast cancer, one of the most aggressive forms of the disease. AAPI women in this age cohort had the second-lowest rate of breast cancer among all racial groups in 2000. “Breast cancer is still more common the older we get, but it’s alarming to see younger women being diagnosed,” said Dr. Helen Chew, director of the clinical breast cancer program at UC Davis Health. Korean, Chinese, Filipina and South Asian American women face the highest risk of breast cancer. Disaggregating data is key to understanding what’s driving the rapid rise in breast cancer among Asian women, Chew said.

Persons: Chi Huang, Huang, ”, Helen Chew, Scarlett Lin Gomez, who’s, ” Gomez, Gomez, Chew, ” Chew, Xers, it’s, “ Organizations: American, Pacific, American Cancer Society, UC Davis Health, University of California, “, South, Filipina, Indians, Pacific Islanders, UCSF Locations: Asia, San Francisco, U.S, Southeast

More younger women are getting breast cancer, and doctors are scrambling to understand why. While having a baby may temporarily increase a woman’s breast cancer risk, it slightly lowers long-term risk, said Dr. Ann Partridge, co-founder and director of the Program for Young Adults with Breast Cancer at the Dana-Farber Cancer Institute. What’s known about breast cancer in younger womenDoctors are still scratching the surface in researching why breast cancer is becoming more prevalent at a younger age. They’re not breastfeeding as much, which does increase breast cancer risk. That would indicate that obesity likely isn’t much of a factor in the rising rates of breast cancer among younger women, said Toriola, of Washington University.

Persons: ”, Alexandra Thomas, “ That’s, —, Adetunji, It’s, menarche, Eleonora Teplinsky, menstruating, Ann Partridge, Dana, “ it’s, it’s, ” Partridge, “, They’re, that’s, ” Teplinsky, Toriola, ” Toriola Organizations: Duke Health, Washington, Cancer, Health, New Jersey . Studies, American Cancer Society, Young, Farber Cancer Institute, Toxicology, Washington University Locations: U.S, New Jersey

☆ Stress and ‘moon face’: What experts say about this TikTok trend
▼ + stars: | 2024-10-17 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +6 min

“It can look swollen and inflamed.”“It’s from high cortisol, aka high stress,” a woman says in another post. How stress can affect the faceWhile cortisol levels from elevated everyday stress may not be the reason behind so-called moon face, the hormone can take a toll on the skin in other ways. “Consistently elevated cortisol levels have been shown to inhibit your skin’s production of collagen, hyaluronic acid and healthy lipids like ceramide,” Bowe told CNN in an earlier interview. Tips for less stressThere are ways to reduce stress that can benefit the skin as well, experts say. In addition, yoga, meditation and deep breathing are all known to decrease cortisol production and stress levels.

Persons: ”, Dr, Rajani, ” Katta, Katta, Whitney Bowe, ” Bowe, Raj Dasgupta, “ It’s, ” Dasgupta, “ Organizations: CNN, Social, Baylor College of Medicine, Johns Hopkins Medicine, Icahn School of Medicine, Mount Sinai Medical, Whole, “, Huntington Health, US Centers for Disease Control Locations: TikTok, Houston, New York City, California

☆ These high-quality growth stocks are must-owns for investors, Trivariate Research says
▼ + stars: | 2024-10-17 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Mounting geopolitical tensions and a tight presidential election may intensify market volatility in coming weeks, but high-quality growth stocks may prove a useful way for investors to hedge against any future uncertainty, according to Trivariate Research. October is a historically volatile month for stocks , and this week alone has seen the market seesaw. "It now seems the market has come full circle," Trivariate Research founder and CEO Adam Parker wrote in a recent research note to clients. "It is much easier to buy and hold growth stocks, and it requires less arrogance in predicting the unknown than it used to. Wholesale retailer Costco and hotel giant Hilton are two other growth names that Parker listed.

Persons: Adam Parker, Parker, Morgan Stanley, Eli Lilly, Lilly Organizations: Research, Dow Jones, Dow, Adobe, Wholesale, Costco, Hilton Locations: U.K, Wednesday's

☆ These 9 biotech stocks have doubled this year and are set to double again, analysts say
▼ + stars: | 2024-10-17 | by ( Ganesh Rao | ) www.cnbc.com time to read: +4 min

Nine health-care stocks have more than doubled in price this year, but still have more than 100% upside potential, according to analysts. All have a "buy" or equivalent rating, and every single one expects the stock to more than double over the next 12 months. The median average price target of $66.50 from eight analysts points to a 252% upside potential over the next 12 months. Benitec is expected to rise by 104% over the next 12 months, according to the median price target of five analysts. Humacyte has doubled this year, and analysts expect it to double again over the next 12 months.

Persons: Benitec, Arcutis, Stocks, Rezolute Rezolute, Trevi, Arcutis Biotherapeutics, Humacyte Organizations: CNBC Pro, Nasdaq, Jasper Therapeutics, Corbus Pharmaceuticals, Rezolute, Trevi Therapeutics, Delcath Systems, Precision Medicines, Jasper Therapeutics Jasper Therapeutics, Pharmaceuticals Corbus Pharmaceuticals, Trevi Therapeutics Trevi Therapeutics, Systems Delcath Systems, Praxis, Medicines Locations: Jasper, Jasper Therapeutics Jasper, Massachusetts, California, U.S, Europe, Australia, Hayward , California

☆ Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.
▼ + stars: | 2024-10-16 | by ( Karen Gilchrist | Karen Gilchrist Is A Reporter For Cnbc.Com. | ) www.nbcnews.com time to read: +4 min

LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K. The weight-loss treatment firm and creator of Zepbound announced Monday that it would commit £279 million ($364 million) to help tackle Britain’s significant health challenges — including obesity. Within that, the five-year trial, conducted in collaboration with Health Innovation Manchester, will also explore how weight-loss drugs impact “participants’ employment status and sick days from work,” the company said in a news release. The use cases for obesity drugs have been growing over recent months, with several drug regulators expanding GLP-1 drug labels for use in treating obesity-related comorbidities and other illnesses. The company said it anticipates making an additional £279 million of new investment into the U.K. over the coming years.

Persons: Eli Lilly, Zepbound, ”, Rachel Batterham, Wes Streeting, Streeting, “ It’s, ” Streeting, Peter Verdault, “, Dr, Dolly van Tulleken, Eli Lilly’s Organizations: LONDON, U.K, of Health, Social, Department for Science, Innovation, Technology, Labour government’s, Investment, National Health Services, Health Innovation, International Medical, British Health, Social Care, Covid, NHS can’t, CNBC, Citi, MRC, University of Cambridge, BBC Radio, Lilly, Labs Locations: Lilly, British, Europe

☆ These AI-powered smart glasses monitor your emotions and your eating habits
▼ + stars: | 2024-10-15 | by ( Katie Balevic | ) www.businessinsider.com time to read: +3 min

Sense glasses analyze facial expressions and track physical activity and eating habits. Emteq CEO Steen Strand said Sense glasses are not yet available for the consumer market. One company wants to help people wearing smart glasses look inward to gain insights into their own health. Another competitor, Meta, recently announced updates to its Ray-Ban smart glasses and showed off its Orion AR glasses, though those may never be made available to the public. "With most smart glasses, the sensors are looking out, whereas the data we are gathering is looking at the wearer," Nduka said.

Persons: Steen Strand, —, Strand, Charles Nduka, Nduka Organizations: Emteq Labs, Service, Snap Inc, Meta, Orion

☆ Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
▼ + stars: | 2024-10-15 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K. The use cases for obesity drugs have been growing over recent months, with several drug regulators expanding GLP-1 drug labels for use in treating obesity-related comorbidities and other illnesses. Speaking to CNBC last week, Citi pharmaceuticals analyst Peter Verdault said the body of evidence to support increased use of weight-loss drugs "keeps coming." The company said it anticipates making an additional £279 million of new investment into the U.K. over the coming years.

Persons: Eli Lilly, Zepbound, Rachel Batterham, Lilly, Wes Streeting, Covid, Streeting, Peter Verdault, Dolly van Tulleken, Eli Lilly's Organizations: LONDON, U.K, Department of Health, Social, Department for Science, Innovation, Technology, Labour government's, Investment, National Health Services, Health Innovation, International Medical, Social Care, CNBC, Citi, MRC, University of Cambridge, BBC Radio, Lilly Locations: Brooklyn, New York, Europe

☆ Zealand Pharma seeks partner for its 'next generation' weight loss drug
▼ + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailZealand Pharma seeks partner for its 'next generation' weight loss drugCNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global partner.

Persons: Karen Gilchrist Organizations: Zealand Pharma

☆ Ozempic is driving up the cost of your health care, whether you can get your hands on it or not
▼ + stars: | 2024-10-11 | by ( Jessica Dickler | ) www.cnbc.com time to read: +2 min

About 165 million Americans rely on employer-sponsored health insurance and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Wegovy and Novo Nordisk's diabetes drug Ozempic. One in three employees are looking for more resources to combat obesity, according to a recent report by consulting firm Gallagher. Glucagon-like peptide-1 treatments such as Wegovy and Ozempic, which mimic hormones produced in the gut to suppress a person's appetite, are considered game changers on this front. Already, prescription drug costs jumped 8.6% last year, due in part to a surge in the use of GLP-1 drugs, according to a recent report by Mercer. "It becomes a lifelong drug," said Gary Kushner, chair and president of Kushner & Company, a benefits design and management company.

Persons: Gallagher, Trilliant, Mercer, Sunit Patel, actuary, Gary Kushner Organizations: Finance, Security, Kushner & Company Locations: U.S, Mercer's

☆ Zealand Pharma targeting 'next generation' of obesity drugs, CEO says
▼ + stars: | 2024-10-11 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailZealand Pharma targeting 'next generation' of obesity drugs, CEO saysZealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover speculation.

Persons: Adam Steensberg Organizations: Zealand Pharma

☆ Ozempic-fueled slimming is blowing up the wedding dress industry
▼ + stars: | 2024-10-11 | by ( Allison Morrow | ) edition.cnn.com time to read: +6 min

New York CNN —Price distortions and dysfunction are nothing new in the $73 billion wedding industry. For better or worse, many brides are using the drugs ahead of their big day, lured in by the promise of rapid weight loss. The right fitThe ideal time to buy a wedding dress is eight to 10 months before the event, according to wedding planning site the Knot, and some planners recommend buying a full year in advance in case of shipping delays. “Usually, the dress was ordered somewhere in the middle of those 50 pounds.”It’s hard to overstate how such drastic weight loss can complicate a wedding dress’ fit. “Weight loss has always been a top of priority.

Persons: CNN Business ’, Tami Luhby, Susan Ruddie, Dresser, Spring, That’s, they’re, ”, Myrna Lundberg, “, Lundberg, ” Lundberg, “ It’s, — it’s, you’re Organizations: CNN Business, New York CNN, FDA, Drug Administration, Bureau of Labor Statistics, CNN Locations: New York, China, Suez, United States

☆ Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
▼ + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

Jaap Arriens | NurPhotoDanish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly . Last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight-loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide. Stock Chart Icon Stock chart icon Zealand Pharma. Novo Nordisk is also experimenting with its own version of the treatment, combining the GLP-1 component Semaglutide with amylin analog Cagrilintide in a candidate called CagriSema. Syringes from weight loss drugs "Wegovy," "Ozempic" and "Mounjaro."

Persons: Jaap Arriens, Eli Lilly, Adam Steensberg, Steensberg Organizations: Zealand Pharma, Novo Nordisk, CNBC, pharma, Nordisk, Union, Getty Locations: U.S

Less than a fifth of large companies in the United States include coverage for the popular but pricey weight loss drugs Wegovy and Zepbound in their health insurance plans, according to a survey published Wednesday in Health Affairs. “They’re trying to figure out what is the right balance between the advantages to employees, potential health benefits and the cost of these drugs. The survey found that about half of employers that cover the weight loss drugs have certain requirements associated with their coverage, which Rae said would limit access for some employees but save money. Among large firms that don’t currently cover GLP-1 drugs for weight loss, only about 3% said they’re “very likely” to do so in the next year. Despite the exorbitant cost, employers do have a positive view of the drugs.

Persons: Wegovy, ”, Matthew Rae, “ They’re, —, Rae, Susan Spratt, Christopher McGowan, Eli Lilly, ” McGowan, “, ” Rae, you’ve, that’s, don’t, they’re Organizations: Health Affairs, “ Employers, Population Health Management, Duke Health, Centers for Disease Control, Novo Nordisk, Research, North Carolina, ” Novo Nordisk Locations: United States, KFF, North Carolina, U.S, Novo

Search resuls for: "Obesity"

25 mentions found